. 2010 Jun 8;12(3):R111. doi: 10.1186/ar3047

Table 3.

Humoral response to vaccination on day 21 in RA patients treated with rituximab

	Controls n = 10	Pre-RTX n = 8	Post-RTX n = 11
Influenza vaccine, % increase
IgM, median (95% CI) responder, n	104 (96-130) 3	120 (98-139) 6	105 (88-132) 4
IgG, median (95% CI) responder, n	115 (96-191) 6	143 (72-176) 5	109 (85-139)^a5
κ-Light chain median (95% CI)	110 (101-145)^a	126 (98-163)	105 (93-124)
λ-Light chain median (95% CI)	126 (98-175)^a	147 (94-154)^a	113 (93-199)^a

Pneumococci vaccine
IgM, median (95% CI) responder, n	148 (92-541)^a8	107 (93-198) 3	105 (77-322) 5
IgG, median (95% CI) responder, n	126 (71-213)^a7	178 (102-335)^a6	107 (88-151)^b4
κ-Light chain median (95% CI)	154 (85/218)^a	124 (97-211)^a	105 (94-171)
λ-Light chain median (95% CI)	164 (98/571)^a	227 (111-308)^a	138 (88-330)^a

Pre-RTX group, RA patients treated with RTX 6 days after vaccination; Post-RTX group, RA patients treated with RTX 6 months before vaccination; Controls, RA patients never treated with RTX. The levels of vaccine-specific antibodies at day 0 were taken as 100%. On day 21, the mean increase of antibody levels in the control group was 110%. This value indicated the cutoff for vaccination response in the RTX-treated patients. CI, Confidence interval.

^aIncrease of Ig levels on day 21 compared with day 0, P < 0.05.

^bIncrease of Ig levels in post-RTX group was lower as compared with pre-RTX group, P < 0.027.